BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
Phase 3
Completed
NCT03762018
| Condition | Pleural Mesothelioma Malignant Advanced |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | ETOP IBCSG Partners Foundation |
|---|
| Status | Completed |
|---|
| Enrollment | 400 participants |
|---|
| Interventions | Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab |
|---|
| Start date | Apr 30, 2019 |
|---|
| Completion date | Sep 1, 2023 |
|---|
| Results posted | May 14, 2026 |
|---|
Summary
The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.
Overall Survival (OS)
From randomization until death from any cause, up to 52 months. · months
| Atezolizumab Plus Bevacizumab Plus Chemotherapy | 20.5 months |
|---|
| Bevacizumab Plus Chemotherapy | 18.1 months |
|---|
| p-value | 0.14 |
|---|
| Hazard Ratio (HR) | 0.84 (95% CI 0.66–1.06) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.